摘要
[目的]了解参附注射液治疗慢性心力衰竭的剂量、溶媒及溶媒剂量情况。[方法]检索中国期刊全文数据库(CNKI),1993年1月—2012年5月文献,查找参附注射液静脉滴注治疗慢性心力衰竭的临床研究。[结果]参附注射液静脉滴注治疗慢性心力衰竭的剂量以40-60 mL应用广泛(80.01%),其中以50 mL应用最多(35.56%),且安全性好;溶媒采用5%葡萄糖注射液居多(81.11%),大多采用剂量250 mL(55.56%);对于合并糖尿病患者,溶媒采用5%葡萄糖注射液或0.9%的生理盐水,多加入胰岛素治疗(50%)。[结论]临床应用参附注射液治疗慢性心力衰竭大多按照说明书,但应加强参附注射液基础和临床的量效关系研究,探索安全、有效的最佳剂量。
[Objective] To investigate the dose,solvent and solvent-dose of Shenfu injection in treating chronic heart failure.[Methods] The China Full-text Journal Database（CNKI）,Jan,1993 to May,2012 was searched,and the clinical studies of Shenfu injection used intravenously for patients with chronic heart failure were found.[Results] The widely used dose of Shenfu injection intravenous infusion in chronic heart failure treatment was within 40~60 mL（80.01%）,among them,50 mL was the most widely applied（35.56%）with better security;5% dextrose injection as solvent was commonly used（81.11%）and the mostly used dose was 250 mL（55.56%）;for patients with diabetes,it was tended to and used 5% dextrose injection or 0.9% saline as solvent add insulin to solvent（50%）.[Conclusion] Shenfu injection in therapy for patients with chronic heart failure are mostly applied as drug instruction.However,the research in basic and clinical dose-effect relationship should be strengthened.The optimal safe and effective dose should be explored.
出处
《天津中医药大学学报》
CAS
2013年第3期164-167,共4页
Journal of Tianjin University of Traditional Chinese Medicine
基金
国家重点基础研究发展计划(973计划)基金项目(2012CB518401)
